Biotech News

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

Pulmonx (LUNG)Pulmonx2026-10-13 20:05 ESTEarnings

REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday,

Related news

IRMDiRadimed2026-10-23 12:30 EST

IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026

IARTIntegra LifeSciences2026-10-06 12:30 EST

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

TMCITreace Medical Concepts2026-10-23 11:05 EST

Treace to Report Third Quarter 2026 Financial Results on November 6, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

STIMNeuronetics2026-10-21 12:30 EST

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

RXSTRxSight2026-10-20 20:05 EST

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

STXSStereotaxis2026-10-20 11:40 EST

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-10-13 20:05 EST

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Stock data

Close: 1.88 USD
Market cap: 68M USD
Exchange: NASDAQ
Sector: MedTech
Location: United States